City Therapeutics priced an initial public offering and is set to begin trading Friday as it builds out an “Alnylam 2.0” RNAi platform. The company’s $200M IPO adds another public-market listing to a rebound year for biotech, with investors backing next-generation RNAi execution and pipeline expansion. The offering underscores how RNAi remains a core funding theme despite the market’s need for clearer clinical signals. For operators and competitors, the new capital pool can accelerate target selection, formulation and delivery work, and advancement of candidate programs toward human testing. City’s framing also suggests direct competition for platform attention—meaning collaborators, CROs, and RNAi tooling providers may see increased demand as companies differentiate on potency, durability, and dosing logistics. Overall, the IPO functions as a near-term read-through for how much risk capital still flows into platform-heavy RNAi stories and how quickly management teams are expected to translate platform claims into trial-ready assets.